CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaëlle Fanciullino, Régis Costello, Laure Farnault et al.|Blood Advances|2018Cited by 43
Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patientsGeoffroy Venton, Régis Costello, Mihai Turcanu et al.|European Journal of Internal Medicine|2019Cited by 25
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Raphaëlle Fanciullino, Mourad Hamimed et al.|Journal of Controlled Release|2021Cited by 9
Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemiaGeoffroy Venton, Rene Costello, H. Adam et al.|Médecine et Maladies Infectieuses|2016Cited by 9
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implicationsMélanie Donnette, Raphaëlle Fanciullino, Geoffroy Venton et al.|Annals of Oncology|2021Cited by 8